QPPV.COM KNOWLEDGE ASSESSMENT

Emicizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Emicizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient on emicizumab develops thrombosis. Which additional information is most important for assessing the product-related risk mechanism?
Question 2 of 10 Why should aggregate analyses generally distinguish patients with FVIII inhibitors from those without inhibitors?
Question 3 of 10 Which follow-up is most appropriate for an unexpected coagulation laboratory result in a patient receiving emicizumab?
Question 4 of 10 Why can emicizumab remain active in a patient with neutralising factor VIII inhibitors?
Question 5 of 10 A patient who was initially well controlled on emicizumab develops recurrent unexpected bleeding. Which assessment is most appropriate?
Question 6 of 10 During perioperative review of a patient receiving emicizumab, which question is most important for understanding treatment-related risk?
Question 7 of 10 Which classification most appropriately distinguishes emicizumab from conventional haemophilia A replacement therapy?
Question 8 of 10 Which set of data is most useful when evaluating a suspected emicizumab medication error followed by bleeding?
Question 9 of 10 Why does inhibitor status need to be captured explicitly in an emicizumab case?
Question 10 of 10 Why is a breakthrough bleed during emicizumab prophylaxis not, by itself, proof of immediate treatment failure?

Select an answer to continue.

QPPV.com